In a systemic review and meta-analysis of 101 articles, which also considered clinical trials and prospective studies, DM was also mainly related to PD-1/PD-L1, with an incidence of 2.0% (95% CI, 0.7–5.8) for nivolumab and 0.4% (95% CI, 0.2–1.3) for pembrolizumab. The gene discussed is CD274; the disease is diabetes mellitus.